Back to discover

Protein / target

Interferon-induced, double-stranded RNA-activated protein kinase

Encoded byEIF2AK2P19525Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Eukaryotic translation initiation factor 2alpha kinase

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene EIF2AK2 · Genetic evidence · score 0.32

Research activity

Emerging research

1 papers · latest 2019

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection.

View complete UniProt function annotation

IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection (PubMed:18835251, PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral replication via the integrated stress response (ISR): EIF2S1/eIF-2-alpha phosphorylation in response to viral infection converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting to a shutdown of cellular and viral protein synthesis, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, PubMed:23399035). Also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation: phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, PubMed:19229320, PubMed:22214662). In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteasomal degradation (PubMed:20395957). Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding pro-inflammatory cytokines and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as both a positive and negative regulator of the insulin signaling pathway (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin (By similarity)

Subcellular location

CytoplasmNucleusCytoplasm, perinuclear region
Domains and Gene Ontology detail (43)

Domains & features

DRBM 1DRBM 2Protein kinase

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Cmembrane
  • Cnucleoplasm
  • Cnucleus
  • Cperinuclear region of cytoplasm
  • Cribosome
  • FATP binding
  • Fdouble-stranded RNA binding
  • Feukaryotic translation initiation factor 2alpha kinase activity
  • Fidentical protein binding
  • Fkinase activity

551 aa · 62 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOKinase signallingUniProt · GOImmune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Kinase signalling

  • ·IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alph…
  • ·eukaryotic translation initiation factor 2alpha kinase activity
  • ·kinase activity
  • ·non-membrane spanning protein tyrosine kinase activity

Immune signalling

  • ·IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alph…
  • ·antiviral innate immune response
  • ·positive regulation of cytokine production

Transcriptional regulation

  • ·IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alph…
  • ·DNA-templated transcription

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene EIF2AK2

Gene-level evidence surfaced through the gene EIF2AK2 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

HIV Infections
0.37Preliminary

Pathway evidence dominant · Open Targets 0.51 · no direct causal or clinical evidence

Neurodegenerative Diseases
0.36Preliminary

Pathway evidence dominant · Open Targets 0.53 · no direct causal or clinical evidence

Virus Diseases
0.33Preliminary

Pathway evidence dominant · Open Targets 0.39 · no direct causal or clinical evidence

Genetic Diseases, Inborn
0.32Limited support

Genetic evidence dominant · Open Targets 0.19

Influenza, Human
0.27Preliminary

Pathway evidence dominant · Open Targets 0.38 · no direct causal or clinical evidence

View evidence synthesis (5)
HIV InfectionsPreliminary
0.37
agreement 0.220.52
Pathway85%Literature14%RNA expression2%

Open Targets aggregate 0.51 · 3 independent evidence families · no direct causal or clinical evidence

Neurodegenerative DiseasesPreliminary
0.36
agreement 0.190.54
Pathway93%Literature7%

Open Targets aggregate 0.53 · 2 independent evidence families · no direct causal or clinical evidence

Virus DiseasesPreliminary
0.33
agreement 0.160.51
Pathway67%Literature33%

Open Targets aggregate 0.39 · 2 independent evidence families · no direct causal or clinical evidence

Genetic Diseases, InbornLimited support
0.32
agreement 0.180.46
Genetic97%Literature3%

Open Targets aggregate 0.19 · 2 independent evidence families

Influenza, HumanPreliminary
0.27
agreement 0.120.41
Pathway88%Literature9%RNA expression3%

Open Targets aggregate 0.38 · 3 independent evidence families · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.53
HIV Infections0.51
Virus Diseases0.39
Influenza, Human0.38
Genetic Diseases, Inborn0.19

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)
SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketSM · Druggable FamilyPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2019

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Lamers MM · Frontiers in immunology · 2019

Recent

ADAR1: "Editor-in-Chief" of Cytoplasmic Innate Immunity.

Lamers MM · Frontiers in immunology · 2019

Europe PMC papers linked directly to this protein.